Skip to content
  • twitter
  • linkedin
  • onxeo
  • SUBSCRIBE TO OUR NEWS
  • EN
  • FR
  • CONTACT
Onxeo

Onxeo

Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

  • COMPANY
    • Profile
    • Management
    • Board of Directors
    • Join us
    • Contact us
  • SCIENCE
    • Scientific Advisory Committee
    • DNA Damage Response
    • platON™
    • Collaborations
  • PRODUCTS
    • DDR Pipeline
    • AsiDNA™
    • OX401
    • Other
  • INVESTORS
    • Regulated Information
      • Press Releases
      • Registration documents
      • Financial Information
      • Shares & Voting Rights
      • Share Repurchase/ Liquidity Agreement
      • Financial operations
      • Sponsor/ Advisor
    • Governance
      • Board Committees & Regulations
      • Directors’ Disclosures
      • Bylaws
    • Shareholder Resources
      • General Meetings
      • Financial Calendar
      • Stock Information
      • Shareholders’ Letters
    • Investor Relations
  • NEWS & EVENTS
    • Press Releases
    • Events & Presentations
    • Shareholder Letters
    • Media

Shareholders’ letters-sh ress

  1. Home
  2. /
  3. Investors
  4. /
  5. Shareholder Resources
  6. /
  7. Shareholders’ letters-sh ress

Shareholder Letters

NEW: AsIDNA™ Letters!

The clinical development of AsiDNA™ is well on its way and we would like to inform you regularly about the progress being made through a Letter dedicated to this first-in-class candidate.

 

AsiDNA™  Letter No. 2
July 18,  2019

Role of AsiDNA™ in the new combination strategies

 

 

 

 

 

 

AsiDNA™  Letter No. 1
July 4,  2019

The field of DDR and the strategic advantages of AsiDNA

 

PREVIOUS SHAREHOLDER LETTERS
  • Letter to Shareholders – January 2019
  • Letter to Shareholders – December 2017
  • Letter to Shareholders – October 2016
  • Letter to Shareholders - December 2015
  • Letter to Shareholders - Beleodaq® – September 2015
  • Letter to Shareholders – September 2015
  • Letter to Shareholders – May 2015
  • Letter to Shareholders – January 2015

INVESTORS

  • REGULATED INFORMATION
    • Press Releases
    • Registration Documents
    • Financial Information
    • Number of Shares and Voting Rights
    • Share Repurchase – Liquidity Agreement
    • Financial operations
    • Sponsor/ Advisor
  • GOVERNANCE
    • Board Committees & Regulations
    • Directors’ Disclosures
    • Bylaws
  • SHAREHOLDER RESOURCES
    • General Meetings
    • Financial Calendar
    • Stock Information
    • Shareholder Letters
  • INVESTOR RELATIONS
Onxeo

> SITE MAP

> LEGAL NOTICES
> FOLLOW US

COMPANY

COMPANY


  • Profile
  • Executive Committee
  • Board of Directors
  • Join us
  • Contact us

SCIENCE

SCIENCE


  • DNA Damage Response
  • platON™
  • Collaborations

PRODUCTS

PRODUCTS


  • Pipeline
  • AsiDNA™
  • OX401
  • belinostat / Beleodaq®

INVESTORS

INVESTORS


  • Regulated Information
  • Governance
  • Shareholder Resources
  • Investor Relations

NEWS AND EVENTS

NEWS & RELEASES


  • Press Releases
  • Events & Presentations
  • NewsLetters
  • Media
SUBSCRIBE TO
OUR NEWS
CONTACT
US

ONXEO SA


49, avenue du Général Martial Valin
75015 PARIS – FRANCE
+33 (0) 1 45 58 76 00

185 Alewife Brook Parkway
Suite 210, Cambridge, MA 02138
(617) 648-8674

© Copyright 2019 Onxeo
Photos : Onxeo - Design : 1sur1.net

Copyright © 2023 Onxeo All rights reserved. Theme: Flash by ThemeGrill. Powered by WordPress